Bonjesta is an anti-nausea drug owned by Duchesnay. First authorised for market use on November 7, 2016, it contains active ingredients Doxylamine Succinate and Pyridoxine Hydrochloride. Bonjesta is available in extended release oral tablet form.
Bonjesta's generic is not yet available, with its last patent set to expire on February 18, 2033. This date signifies the earliest possible release of the Bonjesta generic.
The active ingredients doxylamine succinate; pyridoxine hydrochloride make Bonjesta effective for the treatment of nausea and vomiting during pregnancy in women who do not respond to conservative management.
Bonjesta is protected by 4 patents with the last one due to expire on February 18, 2033. This implies the earliest availability of Bonjesta generic. Below are the details of the patent: